{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:26:03Z","timestamp":1773393963684,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lana.2025.101347","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:53:38Z","timestamp":1767164018000},"page":"101347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expanding the neurological spectrum of HTLV-1 beyond HAM\/TSP: a contemporary perspective"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7694-7223","authenticated-orcid":false,"given":"Abelardo Q.C.","family":"Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Tulius T.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2025.101347_bib1","series-title":"WHO announces the development of new recommendations on HTLV-1","year":"2025"},{"issue":"11","key":"10.1016\/j.lana.2025.101347_bib2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1586\/1744666X.2014.966690","article-title":"Inflammatory manifestations of HTLV-1 and their therapeutic options","volume":"10","author":"Martin","year":"2014","journal-title":"Expet Rev Clin Immunol"},{"issue":"8452","key":"10.1016\/j.lana.2025.101347_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis","volume":"2","author":"Gessain","year":"1985","journal-title":"Lancet"},{"issue":"8488","key":"10.1016\/j.lana.2025.101347_bib4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV-I associated myelopathy, a new clinical entity","volume":"1","author":"Osame","year":"1986","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.lana.2025.101347_bib5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(06)70628-7","article-title":"The HTLV-1 neurological complex","volume":"5","author":"Araujo","year":"2006","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.lana.2025.101347_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/civ229","article-title":"Neurological manifestations in human T-Cell lymphotropic virus type 1 (HTLV-1)-Infected individuals without HTLV-1-associated myelopathy\/tropical spastic paraparesis: a longitudinal cohort study","volume":"61","author":"Tanajura","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.lana.2025.101347_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200147","article-title":"Imaging spectrum of HTLV-1-related neurologic disease: a pooled series and review","volume":"13","author":"Dixon","year":"2023","journal-title":"Neurol Clin Pract"},{"issue":"12","key":"10.1016\/j.lana.2025.101347_bib8","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2967\/jnumed.116.175083","article-title":"Evidence of brain inflammation in patients with human T-lymphotropic virus type 1-associated myelopathy (HAM): a pilot, multimodal imaging study using 11C-PBR28 PET, MR T1-weighted, and diffusion-weighted imaging","volume":"57","author":"Dimber","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lana.2025.101347_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2014.03.1374","article-title":"Temporal lesions and widespread involvement of white matter associated with multi-organ inflammatory disease in human T-lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"25","author":"Mendes","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.lana.2025.101347_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00415-018-8777-z","article-title":"Human T-cell lymphotropic virus (HTLV)-associated encephalopathy: an under-recognised cause of acute encephalitis? Case series and literature review","volume":"265","author":"Crawshaw","year":"2018","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.lana.2025.101347_bib11","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/v16101569","article-title":"Cognitive assessment in HTLV-1 patients followed up at a reference center in Salvador, Brazil","volume":"16","author":"Bordallo","year":"2024","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.lana.2025.101347_bib12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/jnnp.74.8.1085","article-title":"Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP\/HAM, asymptomatic carriers, and healthy controls","volume":"74","author":"Silva","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lana.2025.101347_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijid.2019.05.010","article-title":"Cognitive impairment in HTLV-1-associated myelopathy, proviral load and inflammatory markers","volume":"84","author":"Champs","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.lana.2025.101347_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/practneurol-2021-003053","article-title":"HTLV-1 encephalitis","volume":"22","author":"Robson","year":"2022","journal-title":"Pract Neurol"},{"issue":"5","key":"10.1016\/j.lana.2025.101347_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13550289609146899","article-title":"Therapeutic trials in 200 patients with HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"2","author":"Nakagawa","year":"1996","journal-title":"J Neurovirol"},{"issue":"1","key":"10.1016\/j.lana.2025.101347_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0022-510X(91)90192-A","article-title":"Leukoencephalopathy in HTLV-I-associated myelopathy\/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy","volume":"106","author":"Kira","year":"1991","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.lana.2025.101347_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1212\/WNL.0b013e3181b6bba9","article-title":"Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy","volume":"73","author":"Biswas","year":"2009","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.lana.2025.101347_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-510X(03)00179-5","article-title":"Neurological manifestations in HTLV-I-infected blood donors","volume":"214","author":"Leite","year":"2003","journal-title":"J Neurol Sci"},{"issue":"8673","key":"10.1016\/j.lana.2025.101347_bib19","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(89)91793-5","article-title":"HTLV-1 and polymyositis in Jamaica","volume":"2","author":"Morgan","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.lana.2025.101347_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12883-015-0275-7","article-title":"Clinical presentation of axial myopathy in two siblings with HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"15","author":"Matsuura","year":"2015","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.lana.2025.101347_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s004010050530","article-title":"The main HTLV-I-harboring cells in the muscles of viral carriers with polymyositis are not macrophages but CD4+ lymphocytes","volume":"92","author":"Higuchi","year":"1996","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.lana.2025.101347_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcv.2012.12.016","article-title":"HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa","volume":"57","author":"Desdouits","year":"2013","journal-title":"J Clin Virol"},{"issue":"5","key":"10.1016\/j.lana.2025.101347_bib23","first-page":"549","article-title":"HTLV-I associated myelopathy (HAM) with cerebellar atrophy presenting a down-beat nystagmus","volume":"35","author":"Waragai","year":"1995","journal-title":"Rinsho Shinkeigaku"},{"issue":"5","key":"10.1016\/j.lana.2025.101347_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ana.1264","article-title":"Dysautonomia in human T-cell lymphotrophic virus type I-associated myelopathy\/tropical spastic paraparesis","volume":"50","author":"Alamy","year":"2001","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.lana.2025.101347_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1590\/S1677-55382007000200016","article-title":"Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals","volume":"33","author":"Castro","year":"2007","journal-title":"Int Braz J Urol"},{"issue":"8","key":"10.1016\/j.lana.2025.101347_bib26","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.wnl.0000180962.47653.5e","article-title":"ALS syndrome in HTLV-I infection","volume":"65","author":"Silva","year":"2005","journal-title":"Neurology"},{"issue":"3 Pt 1","key":"10.1016\/j.lana.2025.101347_bib27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.42.3.658","article-title":"Recurrent encephalopathy and seizures in a US native with HTLV-I-associated myelopathy\/tropical spastic paraparesis: a clinicopathologic study","volume":"42","author":"Smith","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.lana.2025.101347_bib28","article-title":"HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"1","author":"Bangham","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.lana.2025.101347_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jcp.10053","article-title":"Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation","volume":"190","author":"Grant","year":"2002","journal-title":"J Cell Physiol"},{"issue":"3","key":"10.1016\/j.lana.2025.101347_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1590\/S0004-282X1993000300005","article-title":"Intravenous methylprednisolone in HTLV-I associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"51","author":"Ara\u00fajo","year":"1993","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"10.1016\/j.lana.2025.101347_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/13550289509111010","article-title":"HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings","volume":"1","author":"Nakagawa","year":"1995","journal-title":"J Neurovirol"},{"issue":"4","key":"10.1016\/j.lana.2025.101347_bib32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s13311-017-0533-z","article-title":"Effectiveness of daily prednisolone to slow progression of human T-lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis: a multicenter retrospective cohort Study","volume":"14","author":"Coler-Reilly","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.lana.2025.101347_bib33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/13550280701397627","article-title":"Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy","volume":"13","author":"Arimura","year":"2007","journal-title":"J Neurovirol"},{"issue":"6","key":"10.1016\/j.lana.2025.101347_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1704827","article-title":"Mogamulizumab (Anti-CCR4) in HTLV-1-associated myelopathy","volume":"378","author":"Sato","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lana.2025.101347_bib35","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s13311-015-0369-3","volume":"12","author":"Boostani","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.lana.2025.101347_bib36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/pathogens13090721","article-title":"A systematical review on ART use in HTLV infection: clinical, virological, and immunological outcomes","volume":"13","author":"Fernandez","year":"2024","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.lana.2025.101347_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1212\/CPJ.0000000000000832","article-title":"Management of HAM\/TSP: systematic review and consensus-based recommendations 2019","volume":"11","author":"Araujo","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"10","key":"10.1016\/j.lana.2025.101347_bib38","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/v16101616","article-title":"Current state of therapeutics for HTLV-1","volume":"16","author":"Wang","year":"2024","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.lana.2025.101347_bib39","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2007-04-085076","article-title":"Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy\/tropical spastic paraparesis patients","volume":"110","author":"Lezin","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lana.2025.101347_bib40","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/v12111242","article-title":"Curcumin as an antiviral agent","volume":"12","author":"Jennings","year":"2020","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.lana.2025.101347_bib41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/acn3.50820","article-title":"Clinical trial of a humanized anti-IL-2\/IL-15 receptor \u03b2 chain in HAM\/TSP","volume":"6","author":"Enose-Akahata","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1016\/j.lana.2025.101347_bib42","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s00415-024-12239-x","article-title":"Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy","volume":"271","author":"Sato","year":"2024","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.lana.2025.101347_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003418","article-title":"Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries","volume":"4","author":"Malhotra","year":"2024","journal-title":"PLOS Glob Public Health"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X25003588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X25003588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:13:30Z","timestamp":1773389610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X25003588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"alternative-id":["S2667193X25003588"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2025.101347","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the neurological spectrum of HTLV-1 beyond HAM\/TSP: a contemporary perspective","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2025.101347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101347"}}